title: Safety and risk of using pediatric donor livers in adult liver transplantation.
abstract: Pediatric donor (PD) livers have been allocated to adult transplant recipients in certain situations despite size discrepancies. We compared data on adults (age > or = 19 years) who underwent primary liver transplantation using livers from either PDs (age < 13 years; n = 70) or adult donors (ADs; age > or = 19 years; n = 1,051). We also investigated the risk factors and effect of prolonged cholestasis on survival in the PD group. In an attempt to determine the minimal graft volume requirement, we divided the PD group into 2 subgroups based on the ratio of donor liver weight (DLW) to estimated recipient liver weight (ERLW) at 2 different cutoff values: less than 0.4 (n = 5) versus 0.4 or greater (n = 56) and less than 0.5 (n = 21) versus 0.5 or greater (n = 40). The incidence of hepatic artery thrombosis (HAT) was significantly greater in the PD group (12.9%) compared with the AD group (3.8%; P =.0003). Multivariate analysis showed that preoperative prothrombin time of 16 seconds or greater (relative risk, 3.206; P =.0115) and absence of FK506 use as a primary immunosuppressant (relative risk, 4.477; P =.0078) were independent risk factors affecting 1-year graft survival in the PD group. In the PD group, transplant recipients who developed cholestasis (total bilirubin level > or = 5 mg/dL on postoperative day 7) had longer warm (WITs) and cold ischemic times (CITs). Transplant recipients with a DLW/ERLW less than 0.4 had a trend toward a greater incidence of HAT (40%; P <.06), septicemia (60%), and decreased 1- and 5-year graft survival rates (40% and 20%; P =.08 and.07 v DLW/ERLW of 0.4 or greater, respectively). In conclusion, the use of PD livers for adult recipients was associated with a greater risk for developing HAT. The outcome of small-for-size grafts is more likely to be adversely affected by longer WITs and CITs. The safe limit of graft volume appeared to be a DLW/ERLW of 0. 4 or greater.
authors.affiliation: Recanati/Miller Transplantation Institute, Mount Sinai Hospital of Mount Sinai/NYU Health, New York, NY, USA. sukru.emre@mountsinai.org
authors.forename: S
authors.initials: S
authors.lastname: Emre
authors.forename: Y
authors.initials: Y
authors.lastname: Soejima
authors.forename: G
authors.initials: G
authors.lastname: Altaca
authors.forename: M
authors.initials: M
authors.lastname: Facciuto
authors.forename: T M
authors.initials: TM
authors.lastname: Fishbein
authors.forename: P A
authors.initials: PA
authors.lastname: Sheiner
authors.forename: M E
authors.initials: ME
authors.lastname: Schwartz
authors.forename: C M
authors.initials: CM
authors.lastname: Miller
mesh_terms: D000293:Adolescent; D000328:Adult; D002779:Cholestasis / Q000209:etiology; D006085:Graft Survival; D006499:Hepatic Artery; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008099:Liver / Q000033:anatomy & histology; D016031:Liver Transplantation; D015999:Multivariate Analysis; D009929:Organ Size; D011183:Postoperative Complications; D011517:Prothrombin Time; D012307:Risk Factors; D012449:Safety; D016559:Tacrolimus / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology; D014019:Tissue Donors
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus